Regulated information PRESS RELEASE TiGenix reports its full year 2014 results Leuven, Belgium - 17 March, 2015 - TiGenix NV , an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, reported its results for 2014 today. Business highlights * Strategic refocusing successfully completed * All resources focused on advancing the allogeneic expanded adipose- derived stem cell product pipeline.
http://ift.tt/1O1OrS2
http://ift.tt/1O1OrS2
No comments:
Post a Comment